CN1927381A - Medicine comprising rilmenidine - Google Patents
Medicine comprising rilmenidine Download PDFInfo
- Publication number
- CN1927381A CN1927381A CN 200610112067 CN200610112067A CN1927381A CN 1927381 A CN1927381 A CN 1927381A CN 200610112067 CN200610112067 CN 200610112067 CN 200610112067 A CN200610112067 A CN 200610112067A CN 1927381 A CN1927381 A CN 1927381A
- Authority
- CN
- China
- Prior art keywords
- rilmenidine
- hypertensive
- chinese medicine
- medicine
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a synergic medicinal composition containing Rilmenidine and Chinese medicinal extracts, and its use in preparing medicament for the treatment of hypertension.
Description
Technical field
The invention belongs to a kind of medicine, a kind ofly specifically be used for the treatment of the hypertensive compositions that contains rilmenidine.
Background technology
Hypertension is common clinical, frequently-occurring disease.A large amount of research is verified, and hypertension is the most important risk factor of cardiovascular and cerebrovascular disease.The whole nation is three hypertension census results show, nineteen fifty-nine the hypertension prevalence of being grown up more than 15 years old be 7.73% for 5.11%:1979; Rose to 11.8% in 1991, and be ascendant trend year by year.At present, there are hyperpietic 9,000 ten thousand people in the whole nation, increase 3,000,000 hypertensive patients every year newly, corresponding therewith, annual apoplexy new cases 1,500,000, about 1,000,000 people of person that die from the apoplexy every year, the existing about 500-600 ten thousand of apoplexy number of patients, wherein about 75% has lost work capacity to some extent, and severe disabled person accounts for more than 40%, annual economic loss and the medical expense that causes thus is quite surprising, brought serious social concern and heavy financial burden to country.So doing a good job of it with prevention, control hypertension is the cardiovascular and cerebrovascular disease preventing and controlling of breach, has been the task of top priority.
At present, though doctor trained in Western medicine has obtained certain progress to hypertensive research, new medicine comes out, and brings new hope to controlling blood pressure, and the most toxic side effect of hypotensor is often taken for a long time and brought many iatrogenic diseases to the patient, loses more than gain.The period in a medicine blood pressure drops, blood pressure easily bounces after the drug withdrawal, and effect is difficult to lasting.Though blood pressure descends sometimes, clinical symptoms is not removed, and what have increases the weight of on the contrary, and the labour force can not recover.And new depressor costs an arm and a leg mostly, and general patient is difficult to bear, and is not inconsistent inconvenient penetration and promotion with China's national situation.In the face of new problem, Chinese medicine has been cooked a large amount of work in recent years preventing and treating aspect the hypertension, obtained gratifying achievement, demonstrated certain advantage, but clinical practice is based on traditional decoction, though curative effect is preferably arranged, so time-consuming because of decocting, the waste medical material, the dosage form transmutability is big, be difficult to problems such as large tracts of land popularization, make the patient be difficult to adhere to for a long time, thereby influenced the normal performance of curative effect, do not reach the intended purposes of control.Filtered out a collection of single medicinal material, though take easy, but because of kind, limited amount, simultaneously, also simple because of the single practical application, can not embody the tcm characteristic that dialectical opinion is controlled, exist the limitation identical too with Western medicine, though be that blood pressure had decline after many patients took medicine, clinical symptoms does not subtract, the irreclaimable problem of labour force.
No matter the Chinese medicine hypertension is controlled in dialectical opinion, and single medicinal material is used and the zoopery aspect proves that all hypotensive effect is definite, and has and have no side effect, and curative effect is lasting, is difficult for advantages such as recurrence.But, be difficult to grasp unfavorable promoting the use because dialectical pattern of syndrome is unfixing.Some single medicine of hiding is effective in cure, but is difficult to solve simultaneous phenomenon, and the single drug effect a little less than, escalated dose problem such as easily have side effects again.
The present invention attempts Chinese medicine and Western medicine are combined, and with the problem of avoiding existing separately, and improves hypertensive therapeutic effect, promptly produces synergism.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of rilmenidine and a kind of Chinese medicine extract, wherein prepare on the basis of the Chinese medicine extract of said composition according to the 6th page of specific embodiment of Chinese patent CN1150930C description, as follows: as to take by weighing 1 part of Ramulus Cinnamomi, 1 part of Radix Paeoniae Rubra, 1 part in Fructus Jujubae, 1 part in Rhizoma Zingiberis Recens, 0.7 part of Radix Glycyrrhizae Preparata, the distilled water that adds 9 times, after water logging half an hour, heating extraction 2 times, boil 30 minutes after-filtration at every turn, residue discards, filtrate was reclaimed, and adds 70% ethanol precipitation, through 20 hours precipitations, decompress filter, discard residue, get and be dissolved in the ethanol part, reclaim ethanol, with 4 times of n-butanol extractions 7 times, each 2.5 hours n-butyl alcohol extractum.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the hypertensive medicine of preparation treatment.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong antihypertensive function, i.e. hypotensive activity.
The following medicine of respectively organizing is awarded spontaneous hypertensive rat (SHR) and mouthful raised administration 15 days, and the result all can obviously reduce the blood pressure of SHR.Experimental result sees the following form.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: extractum 0.93g/kg body weight as indicated above
3 rilmenidine groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight rilmenidine+extractum 0.93g/kg body weight mentioned above is irritated stomach.
Group (n=10) | Blood pressure mmHg | ||
0 day | 5 days | 15 days | |
Group 1 | 149.7±4.9 | 161.7±4.0 | 172.9±7.9 |
Group 2 | 144.8±3.9 | 136.1±2.9 | 131.6±4.6 |
Group 3 | 146.7±4.1 | 129.3±3.7 | 119.8±1.9 |
Group 4 | 149.3±2.9 | 111.2±3.5 | 117.8±5.9 |
This table shows that all there is significant difference (P<0.05) in each group (pure Chinese drug-treated group, rilmenidine group, compositions group) of treatment with model control group, and all there are significant difference (P<0.05) in compositions group and pure Chinese drug-treated group, compositions group and rilmenidine group.Show that there are cooperative effect in rilmenidine and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio rilmenidine and described Chinese medicine extract at 1: 93.
Can produce the capsule that contains following component in a conventional manner:
Component Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Pulvis Talci 5.0
Wherein compositions is made up of with weight ratio rilmenidine and described Chinese medicine extract at 1: 93.
Claims (2)
1 one kinds of hypertensive compositionss of treatment, it was made up of rilmenidine and Chinese medicine extract in 1: 93 by weight, wherein Chinese medicine extract is obtained by following method: take by weighing by weight 1 part of Ramulus Cinnamomi, 1 part of Radix Paeoniae Rubra, 1 part in Fructus Jujubae, 1 part in Rhizoma Zingiberis Recens, 0.7 part of Radix Glycyrrhizae Preparata, the distilled water that adds 9 times, after water logging half an hour, heating extraction 2 times is boiled 30 minutes after-filtration at every turn, residue discards, filtrate was reclaimed, and adds 70% ethanol precipitation, through 20 hours precipitations, decompress filter, discard residue, get and be dissolved in the ethanol part, reclaim ethanol, with 4 times of n-butanol extractions 7 times, each 2.5 hours n-butyl alcohol extractum.
The purposes of 2 compositionss as claimed in claim 1 in the hypertensive medicine of preparation treatment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610112067XA CN100381163C (en) | 2006-08-29 | 2006-08-29 | Medicine comprising rilmenidine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200610112067XA CN100381163C (en) | 2006-08-29 | 2006-08-29 | Medicine comprising rilmenidine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1927381A true CN1927381A (en) | 2007-03-14 |
CN100381163C CN100381163C (en) | 2008-04-16 |
Family
ID=37857613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200610112067XA Expired - Fee Related CN100381163C (en) | 2006-08-29 | 2006-08-29 | Medicine comprising rilmenidine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100381163C (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732687B (en) * | 2009-12-30 | 2011-06-22 | 罗丹晓 | Methyldopa-containing medicament |
CN102351710A (en) * | 2011-10-21 | 2012-02-15 | 合肥工业大学 | Preparation method of medicine intermediate di-cyclopropyl methylamine |
WO2021158059A1 (en) * | 2020-02-07 | 2021-08-12 | 건국대학교 글로컬산학협력단 | Composition comprising rilmenidine compound as active ingredient for treatment of fragile x syndrome or related developmental disability |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1150930C (en) * | 2001-10-26 | 2004-05-26 | 中国中医研究院中药研究所 | Cinnamon twig decoction extract for preventing and curing hypertension |
CN1625404A (en) * | 2002-01-30 | 2005-06-08 | 法马西亚公司 | Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions |
-
2006
- 2006-08-29 CN CNB200610112067XA patent/CN100381163C/en not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732687B (en) * | 2009-12-30 | 2011-06-22 | 罗丹晓 | Methyldopa-containing medicament |
CN102351710A (en) * | 2011-10-21 | 2012-02-15 | 合肥工业大学 | Preparation method of medicine intermediate di-cyclopropyl methylamine |
CN102351710B (en) * | 2011-10-21 | 2013-11-27 | 合肥工业大学 | Preparation method of medicine intermediate di-cyclopropyl methylamine |
WO2021158059A1 (en) * | 2020-02-07 | 2021-08-12 | 건국대학교 글로컬산학협력단 | Composition comprising rilmenidine compound as active ingredient for treatment of fragile x syndrome or related developmental disability |
Also Published As
Publication number | Publication date |
---|---|
CN100381163C (en) | 2008-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103272170B (en) | Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer | |
CN101214304A (en) | Chinese medicine prescription for treating chronic cholecystitis | |
CN100381163C (en) | Medicine comprising rilmenidine | |
CN101732688B (en) | Amlodipine-containing medicament | |
CN101773657B (en) | Medicine containing sodium nitroprusside | |
CN101049438A (en) | Composition of Chinese traditional medicine for treating coronary heart disease | |
CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
CN101732689B (en) | Minoxidil-containing medicament | |
CN100367959C (en) | Medicine contg. irbesartan | |
CN100367956C (en) | Medicine for treating hypertension | |
CN101708326B (en) | Medicine containing nifedipine | |
CN101708325B (en) | Medicine containing propranolol | |
CN101439178B (en) | Medicament containing Urapidil | |
CN101732687B (en) | Methyldopa-containing medicament | |
CN101502635B (en) | Medicament composition containing Reserpine | |
CN1299743C (en) | Pressure lifting oral administration liquor of astragalus root | |
CN101732686B (en) | Metoprolol-containing medicament | |
CN101810839B (en) | Diltiazem-containing medicine | |
CN101810840B (en) | Medicament containing terazosin | |
CN101773658B (en) | Medicine containing indapamide | |
CN1911277A (en) | Medicine for treating leukopenia | |
CN102430073A (en) | Medicinal composition for treating peptic ulcer | |
CN102552711A (en) | Chinese medicinal composition for treating hypertension | |
CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
CN1634541A (en) | Medicine for treating fatigue syndrome and preventing presenility, and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |